ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 187

Detection of Power Doppler Ultrasound Signals in Rheumatic Diseases Using Superb Microvascular Imaging (SMI): Comparison with Conventional Power Doppler Ultrasound

Kazuhiro Yokota1, Takuma Tsuzuki Wada2, Yuji Akiyama2 and Toshihide Mimura3, 1Department of Rheumatology & Applied Immunology, Faculty of Medicine, Saitama Medical University, Irama, Japan, 2Department of Rheumatology & Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma, Japan, 3Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biologic agents, methotrexate (MTX), Rheumatic disease, rheumatoid arthritis (RA) and ultrasonography

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 8, 2015

Session Title: Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The detection of power Doppler (PD) ultrasound signals in joints may be considered as the presence of joint inflammation, i.e., synovitis which is a predictor of erosive progression in rheumatoid arthritis (RA). Superb Microvascular Imaging (SMI), a novel ultrasonography, is based on the sensitive Doppler technology with low-motion artifacts than conventional power Doppler ultrasound (cPDUS); furthermore, it can detect low-velocity blood flow signals with high resolution frame rates. Therefore, we evaluated PD ultrasound signals in patients with rheumatic diseases using SMI and cPDUS, and compared the correlations of these signals to clinical and laboratory assessments by these two imaging modalities. Moreover, we also investigated PD ultrasound signals in the difference between synthetic and biological disease-modifying antirheumatic drugs in patients with RA.

Methods: Twenty-seven patients with RA and 11 non-RA patients with rheumatic diseases were enrolled. We assessed PD signals in the finger, hand, elbow, and knee joints (total 26 joints) by the SMI and cPDUS findings using Aplio 300 (Toshiba Medical Systems). The signals were semiquantified into 4 grades (OMERACT standard, grades 0–3). These individual scores added together to calculate the total SMI score or total cPDUS score (0-114).

Results: The total SMI score was significantly higher than the total cPDUS score in patients with RA (SMI 12.3±11.5 vs. cPDUS 5.2±8.1, p<0.001). On the other hand, there was no significant difference between the total SMI and cPDUS scores in patients with non-RA (SMI 0.6±0.7 vs. cPDUS 0.3±0.6, p=0.1320). Serum CRP and MMP-3 levels, and HAQ-DI score significantly correlated with the total SMI score in patients with RA (CRP: r=0.51, p=0.006; MMP-3: r=0.52, p=0.006; HAQ-DI score: r=0.41, p=0.040). However, these data did not show up the result of correlation with the total cPDUS score (CRP: r=0.22, p=0.260; MMP-3: r=0.26, p=0.205; HAQ-DI score: r=0.21, p=0.295). In non-methotrexate-treated patients with RA, the total SMI score was significantly higher than the total cPDUS score (n=19, SMI 13.3±11.8 vs. cPDUS 4.1±6.2, p=0.001). In contrast, in methotrexate-treated patients with RA, there was no significant difference between the total SMI and cPDUS scores (n=8; SMI 10.0±10.5 vs. cPDUS 7.8±12.1, p=0.188).

Conclusion: Our results suggest that SMI can detect PD ultrasound signals more sensitively than cPDUS in patients with RA. Furthermore, it is a requirement for us to pursuit the result of analysis using SMI and cPDUS.


Disclosure: K. Yokota, None; T. T. Wada, None; Y. Akiyama, None; T. Mimura, None.

To cite this abstract in AMA style:

Yokota K, Wada TT, Akiyama Y, Mimura T. Detection of Power Doppler Ultrasound Signals in Rheumatic Diseases Using Superb Microvascular Imaging (SMI): Comparison with Conventional Power Doppler Ultrasound [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/detection-of-power-doppler-ultrasound-signals-in-rheumatic-diseases-using-superb-microvascular-imaging-smi-comparison-with-conventional-power-doppler-ultrasound/. Accessed December 13, 2019.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/detection-of-power-doppler-ultrasound-signals-in-rheumatic-diseases-using-superb-microvascular-imaging-smi-comparison-with-conventional-power-doppler-ultrasound/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.